Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 56
Summary
- Conditions
- Lymphoma, B Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma Non-Hodgkin
- Lymphoma, Nonhodgkin
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03483103
- Collaborators
- Not Provided
- Investigators
- Study Director: Nick Trede, MD, PhD Juno Therapeutics, Inc.